Gladstone NOW: The Campaign Join Us on the Journey ✕
31 - 45 of 100 Results Clear All
The cells constantly survey the brain to prevent spontaneous seizures, Gladstone scientists discover
News Release Research (Publication) Multiple Sclerosis Alzheimer’s Disease Neurological Disease Akassoglou Lab Palop Lab Imaging
Long-time Gladstone supporter helps scientists pursue Alzheimer’s disease research
Donor Stories Alzheimer’s Disease
The Dolby family has supported Gladstone research since 2015
Donor Stories Alzheimer’s Disease
The 2020 Berkelhammer Scholars break new ground in research on dementias, Parkinson’s disease, and neuropsychiatric disorders
Donor Stories Parkinson’s Disease Alzheimer’s Disease Dementia Neurological Disease Akassoglou Lab Kreitzer Lab Mahley Lab Mucke Lab Nakamura Lab
San Francisco Business Times—Gabaeron, founded by Gladstone President Emeritus Bob Mahley, MD, PhD, and Therini Bio (formerly Medared), founded upon work by Senior Investigator Katarina Akassoglou, PhD, are among Bay Area biotech companies focusing on neurological diseases that collectively raised more than $3 billion from venture capital firms and the public capital markets in 2020.
Gladstone Experts Parkinson’s Disease Multiple Sclerosis Alzheimer’s Disease Neurological Disease Akassoglou Lab Mahley Lab
Drug Target Review—Senior Investigator Katerina Akassoglou, PhD, explains her team’s recent discovery of the immune cells in the brain that promote neurodegeneration in diseases such as multiple sclerosis and Alzheimer’s disease.
Gladstone Experts Multiple Sclerosis Alzheimer’s Disease Neurological Disease Akassoglou Lab
A new lab to study the impact of lived experiences on developing Alzheimer’s disease
Institutional News News Release Profile Alzheimer’s Disease Data Science and Biotechnology Neurological Disease Corces Lab Aging
With an estimated 44 million diagnosed with Alzheimer’s disease worldwide, research is moving quickly to better understand the disease.
Gladstone Experts Alzheimer’s Disease Neurological Disease Mahley Lab Mucke Lab
ImmunoFrontiers—Senior Investigator Katerina Akassoglou, PhD, describes her lab's recent discovery of the genetic mechanisms that drive brain inflammation in neurodegenerative diseases.
Gladstone Experts Parkinson’s Disease Multiple Sclerosis Alzheimer’s Disease Neurological Disease Akassoglou Lab
New study shows reducing levels of the protein tau prevents core autism symptoms in animal models
News Release Research (Publication) Behavioral Core Histology and Light Microscopy Core Alzheimer’s Disease Neurological Disease Mucke Lab
With $4.8 million from the NIH, Gladstone scientists will investigate how the protein apoE4 causes neurodegeneration in Alzheimer’s disease.
Grants News Release Alzheimer’s Disease Neurological Disease Krogan Lab Mahley Lab
New study shows potentiating a subset of NMDA receptors may be beneficial in Alzheimer’s disease and Dravet syndrome.
News Release Research (Publication) Alzheimer’s Disease Epilepsy Neurological Disease Palop Lab
New study shows how patterns in brain activity can be an early predictor of Alzheimer’s symptoms.
News Release Research (Publication) Behavioral Core Alzheimer’s Disease Dementia Center for Systems and Therapeutics Neurological Disease Huang Lab Stem Cells/iPSCs
Jorge Palop and Katerina Akassoglou received an NIH grant to study the link between neurovascular dysfunction and cognitive decline in Alzheimer’s disease.
News Release Research (Publication) Alzheimer’s Disease Neurological Disease Akassoglou Lab Palop Lab
Since Shinya Yamanaka discovered a method to create human induced pluripotent stem (iPS) cells, Gladstone researchers have built on this technology to create numerous iPS cell lines, coax iPS cells into a myriad of tissue types, use them as a tool to study disease, and even begin creating therapies using these cells.
Research (Publication) Stem Cell Core Huntington’s Disease Alzheimer’s Disease Finkbeiner Lab Huang Lab McDevitt Lab Srivastava Lab Yamanaka Lab CRISPR/Gene Editing
